SCHEMBL25575166

SCHEMBL25575166

CCOC(=O)/C=C/c1c(O)cc(F)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.52
CNKSR1 Q969H4 2/20 0.52
TTR P02766 1/20 0.51
DPP4 P27487 1/20 0.51
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA7 P43166 1/20 0.48
CA9 Q16790 1/20 0.48
CA14 Q9ULX7 1/20 0.48
MAOB P27338 1/20 0.47
ESR1 P03372 1/20 0.41
XPO1 O14980 1/20 0.41
EPAS1 Q99814 1/20 0.41
AKT1 P31749 1/20 0.40
APP P05067 1/20 0.40
FDPS P14324 1/20 0.39
HSD17B1 P14061 1/20 0.39
HSD17B2 P37059 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9889446 0.91 CYP3A4 (0.50) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL8807071 0.87 CNKSR1 (0.47) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL8807065 0.87 CNKSR1 (0.47) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL11837087 0.80 CA12 (0.58) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL2200034 0.79 CNKSR1 (0.51) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL15282396 0.79 CYP3A4 (0.48) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL2200033 0.79 CNKSR1 (0.51) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL15282398 0.79 CYP3A4 (0.48) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL14370627 0.79 CNKSR1 (0.54) CYP3A4CNKSR1TTRDPP4CA12
SCHEMBL3912925 0.78 MAOB (0.48) CYP3A4CNKSR1TTRDPP4CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 US disclosed
CN-118451066-A 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure 辉瑞大药厂 2024-08-06 CN disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 CYP3A4 720/4885CNKSR1 878/4885TTR 1714/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 CYP3A4 720/4885CNKSR1 878/4885TTR 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.